App-Quantinova.ai

Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis

Atul Deodhar - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

LY2439821

Longitudinal Tends of Hospitalizations for Giant Cell Arteritis: A 21-year Longitudinal National Population-based Study

Amy Trang - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Tocilizumab

Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus

Mark Lazarus - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

MDX1333

Lowering Expectations: Glucocorticoid Tapering Among Veterans with Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy

Beth Wallace - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Glucocorticoid

Lung Involvement in VEXAS Syndrome

Marta Casal Moura - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort

Eugene Krustev - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Neuropsychiatric systemic lupus erythematosus

N/A

MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Christina Charles-Schoeman - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

ABT-494

Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis

Tate Johnson - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

N/A

Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs

Xavier Mariette - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Filgotinib

Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages

Spencer Jones - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Inositol

Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort

Yann Becker - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Dyslipidemia

Prednisone

Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice

Jyotsna Soundararajan - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis

Despina Michailidou - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Wegener's granulomatosis

Cyclosporine eent

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus

Alfredo Aguirre - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study

Shi-Nan Luong - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis

Alen Zabotti - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriasis

guselkumab (IV)

Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies

William Tillett - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Grace

Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries

Gareth Jones - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Axial spondyloarthritis

N/A

Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

Paul Newcombe - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

MDX1333

Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis

Felice Rivellese - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Filters

45280 Abstracts